A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P
A phase 3 trial of PM8002, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
Overview
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) is a phase 3 interventional study registered as NCT07361510 by Bristol-Myers Squibb, with 750 participants planned, started 2026-03-12 and due to reach its primary completion in 2031-10-14. Interventions recorded: Pumitamig, Pembrolizumab. Conditions listed: Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
- TrialA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G
Shares Bristol Myers Squibb, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
Shares PM8002, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced
Shares PM8002, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Shares PM8002, Bristol Myers Squibb.
- TrialA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer, Non-small-cell lung cancer.